Preclinical trials of a new pharmaceutical drug to treat ovarian cancer have produced successful results, dramatically limiting tumor growth and decreasing tumor mass. Designed specifically for ovarian cancers resistant to traditional therapies, the new radiopharmaceutical can be produced in 25 minutes at low cost, leading to better efficiency compared to alternative methods. This research was presented at the 2021 annual meeting of the Society of Nuclear Medicine and Molecular Imaging.
According to the American Cancer Society, more than 20,000 women are diagnosed with ovarian cancer each year and about 14,000 will die from the disease. Patients with ovarian cancer have a five-year survival rate of 49.1%. It is the fifth leading cause of cancer death among women.
In the study, researchers used a new generating system to develop Pb-214-TCMC-trastuzumab-targeted alpha-therapy to treat HER2-positive ovarian cancer. Ovarian cancer cells and ovarian mice cancer tumors were divided into three groups: those treated with Pb-214-TCMC-trastuzumab, those treated with Pb-214-TCMC-IgG, and an untreated control group. All groups were imagined over time to determine the effectiveness of treatment.
Compared with the control and Pb-214-TCMC-IgG groups, the tumor signal for mice and cells treated with Pb-214-TCMC-trastuzumab decreased dramatically throughout the study, indicating efficacy. of therapy. There was none adverse side effects of the treatment determined by the weight loss of all surviving animals.
“The short 27-minute half-life of Pb-214 is ideal for splitting alpha particle therapeutic applications, “said Mike Zamiara, author of the study and president of Niowave Inc. in East Lansing, Michigan.” The generator system can provide Pb-214 every hour, potentially providing a new source of alpha particle therapy to patients at a lower cost. In the future, the generating system will be available for many therapeutic products in a turnkey system under development, providing reliable doses to improve patient care. ”
Abstract 93. “Therapeutic efficacy of Pb-214-labeled Trastuzumab in a preclinical model of ovarian cancer,” Abdullah Metebi, Comparative Medicine and Integrative Biology, Michigan State University, East Lansing, Michigan; Chelsea Nayback, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan; Jinda Fan, departments of Radiology and Chemistry, Institute of Quantitative Health Sciences and Engineering, Michigan State University, East Lansing, Michigan; Nathan Johnson, John Diemer, Terry Grimm, Mike Zamiara, Niowave, Inc., Lansing, Michigan; and Kurt Zinn, Radiology and Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan.
Provided by the Society of Nuclear Medicine and Molecular Imaging
Citation: Promising treatment of ovarian cancer is effective and efficient (2021, June 11), retrieved June 11, 2021 at https://medicalxpress.com/news/2021-06-ovarian-cancer-treatment- effective-efficient.html
This document is subject to copyright. Apart from any fair treatment for the purposes of private study or research, no part may be reproduced without written permission. Content is provided for informational purposes only.